A phase II study of preoperative chemotherapy cosisting docetaxel, oxaliplatin and S-1 for the clinical Stage III gastric cancer

Not Applicable

• Conditions: Gastric cancer

• Registration Number: JPRN-UMIN000017652
• Lead Sponsor: Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-05-22
• Last Update Posted: 17 October 2023
• Study Completion: 2024-03-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2) Past history of severe hypersensitivity to drugs. 3) Active infection. 4) Severe complications (interstitial pneumonia, pulmonary fibrosis, renal failure, liver failure, heart failure, uncontrollable diabetes millutus and Uncontrollable hypertension) 5) Peripheral motor neuropathy or peripheral sensory neuropathy by any reason. 6) Edema of limbs and trunk by any reason. 7) Continuous systemic steroid therapy. 8) Under treatment with flucytosine, phenytoin, or warfarin. 9) Abnormal electrocardiogram or severe cardiovascular disease. 10) Severe diarrhea. 11) Positive HBs antigen. 12) Pregnant women, or women with the possibility of the pregnancy and men who want let to pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
3-year progression-free survival

Secondary Outcome Measures

Name	Time	Method
Overall survival, Progression-free survival, Response rate of preoperative chemotherapy, Pathological response rate, R0 resection rate, Proportion of adverse events.